Triciribine overcomes in vitro ZNF217-induced doxorubicin resistance in breast cancer cells, and in mice experiments is more effective in inhibiting tumor growth of ZNF217-overexpressing cells than control tumors [30]. Here, ZNF217 is linked to breast cancer.